Revance and Teoxane announced that RHA Dynamic Volume is now available. RHA Dynamic Volume, formerly RHA 4 Mepi, is a product designed with unique rheology to adapt to facial movements and deliver natural-looking results.

FDA-approved for cheek augmentation and/or age-related midface contour deficiencies, RHA Dynamic Volume offers providers the option to address volume loss by restoring both dynamic superficial fat, which moves with facial expressions, and/or static deep fat, which provides foundational support, for up to one year. 

"RHA Dynamic Volume represents the next chapter of the Teoxane RHA Collection," shared Nadeem Moiz, CEO of Revance. "This launch underscores the product's ability to meet the growing demand for fillers that deliver natural-looking, dynamic results. With the expanded midface indication, RHA Dynamic Volume continues to set the standard for facial rejuvenation by combining adaptability, resiliency, and long-lasting results."

Using Teoxane's ATP approach (Anatomy, Assessment & Aging, Technique, Product) and the Teoxane MLT Multilayering Technique, providers can achieve precise, tailored results while prioritizing safety by avoiding high-risk vascular zones. Paired with the Teoxane MLT Multilayering Technique, RHA Dynamic Volume addresses midface volume loss by restoring deep structural support and enhancing superficial dynamic contours, delivering tailored, natural-looking results.

"RHA Dynamic Volume represents a strong demonstration of our commitment to uniting advanced technology, scientific excellence, and a truly patient‑centered approach to facial rejuvenation," said Can Ongen, COO at Teoxane. "When combined with Teoxane's MLT Multilayering Technique, RHA Dynamic Volume provides natural‑looking midface results that align with the expectations of today's aesthetic patients."

Patient satisfaction data further demonstrates the effectiveness of RHA Dynamic Volume. In clinical studies, approximately 98% of patients reported natural-looking results in the midface at 2 months, while over 94% reported natural-feeling results at rest and in motion at 1 year. In clinical trials, RHA Dynamic Volume demonstrated a favorable safety profile, with no late-onset or serious treatment-related adverse events, and no events deemed to be granulomas or delayed inflammatory responses.

Learn more about the Teoxane RHA Collection at rha.revanceaesthetics.com.